Contribution of common and rare genetic variants in CEP72 on vincristine‐induced peripheral neuropathy in brain tumour patients

Studies implicated a role for a genetic variant in CEP72 in vincristine‐induced peripheral neuropathy. This study aims to evaluate this association in a cohort of brain tumour patients, to perform a cross‐disease meta‐analysis and explore the protein‐coding region of CEP72.

[1]  M. Debeljak,et al.  Association of CEP72 rs924607 TT Genotype with Vincristine-induced Peripheral Neuropathy Measured by Motor Nerve Conduction Studies , 2020, Klinische Pädiatrie.

[2]  R. Ono,et al.  Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy , 2020, International Journal of Hematology.

[3]  M. Relling,et al.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later , 2019, Clinical pharmacology and therapeutics.

[4]  Elizabeth M. Wells,et al.  Genetic Variants Associated With Vincristine‐Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia , 2019, Clinical pharmacology and therapeutics.

[5]  W. Leppert,et al.  Mechanisms of Chemotherapy-Induced Peripheral Neuropathy , 2019, International journal of molecular sciences.

[6]  M. Relling,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update , 2019, Clinical pharmacology and therapeutics.

[7]  Smita H. Karande,et al.  Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes , 2018, Clinical pharmacology and therapeutics.

[8]  H. Tamim,et al.  Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study , 2018, Pharmacogenetics and genomics.

[9]  D. Curtis.  A weighted burden test using logistic regression for integrated analysis of sequence variants, copy number variants and polygenic risk score , 2018, European Neuropsychopharmacology.

[10]  M. H. van den Berg,et al.  Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. , 2017, Critical reviews in oncology/hematology.

[11]  M. Coenen,et al.  The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies. , 2017, Pharmacogenomics.

[12]  Cheng Cheng,et al.  An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia , 2017, Clinical pharmacology and therapeutics.

[13]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[14]  E. Lopez-Lopez,et al.  Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. , 2016, Pharmacogenetics and genomics.

[15]  Mitchell J. Machiela,et al.  LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants , 2015, Bioinform..

[16]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[17]  Elizabeth M. Wells,et al.  Patterns and severity of vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia , 2015, Journal of the peripheral nervous system : JPNS.

[18]  Jie J. Zheng,et al.  Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. , 2015, JAMA.

[19]  Naoto Okada,et al.  Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy , 2014, Journal of clinical medicine research.

[20]  I. Adzhubei,et al.  Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.

[21]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[22]  D. Curtis.  A rapid method for combined analysis of common and rare variants at the level of a region, gene, or pathway , 2012, Advances and applications in bioinformatics and chemistry : AABC.

[23]  B. Faircloth,et al.  Primer3—new capabilities and interfaces , 2012, Nucleic acids research.

[24]  Hans-Peter Lipp,et al.  Toxicity of platinum compounds , 2003, Expert opinion on pharmacotherapy.

[25]  A. Ganser,et al.  Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL , 1995, Annals of Hematology.

[26]  W. Bradley,et al.  The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. , 1970, Journal of the neurological sciences.

[27]  E. Smith,et al.  Vincristine-induced peripheral neuropathy in pediatric cancer patients. , 2016, American journal of cancer research.

[28]  Pooja Dewan,et al.  Vincristine induced neurotoxicity in cancer patients , 2010, Indian journal of pediatrics.

[29]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[30]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[31]  W. Kamps,et al.  Vincristine revisited. , 1999, Critical reviews in oncology/hematology.